Cambridge, UK, 22 February 2016: Axol Bioscience, a biotechnology company specialising in the use of stem cell technology to manufacture disease relevant cell based assay systems for the drug discovery industry, today announced Paul Andrews as their Scientific Advisory Board Member. Dr Andrews is an expert in the industrial application of stem cells in phenotypic screening, having previously used this platform to identify agents that steer cell fate. He will aid Axol in ensuring its commercially available human primary and induced pluripotent stem cell (iPSC)-derived cells continue to enable the development of pathophysiologically-relevant systems for industrial and academic research.

Paul Andrews, BSc PhD FRSB is Director of Operations at the National Phenotypic Screening Centre (NPSC), a new open collaborative venture based at the Universities of Dundee, Oxford and Edinburgh. Dr Andrews also sits on the editorial board for Current Research in Drug Discovery and is a Fellow of the Royal Society of Biology. He has been a Trustee of the British Society of Cell Biology, Advisory Board Member of the Scottish Stem Cell Network and was team leader in Cellartis/Cellectis Stem Cells. Prior to this he was team leader for the Stem Cell Technology Programme in the Drug Discovery Unit at The University of Dundee and has over 20 years of postdoctoral research experience in cell and molecular biology.

Dr Paul Andrews, SAB Member, Axol Bioscience said, ‘The time is right to move away from the reductionist target-based approach for drug screening towards using an information-rich phenotypic platform. I’m certain this approach will have a major role to play in the future of drug discovery and development. Axol’s experience in providing a wide range of iPSC-derived cell types and genome editing services to industry offers researchers a reputable resource to tackle complex diseases.’ Dr Yichen Shi, CEO, Axol Bioscience commented, ‘We’re excited to have Dr Andrews on board. His interdisciplinary approach and experience using human iPSCs and embryonic stem cells (ESCs) for high throughput phenotypic drug screening will help ensure we continue to supply cells that drive the development of pathophysiologically-relevant assays to improve drug discovery efficiency.’

Press enquiries
Dr Michelle Ricketts
Axol Bioscience
T: +44 1223 751051
E: m.ricketts@axolbio.com
W: www.axolbio.com

NOTES TO EDITOR
About Axol Bioscience

Axol was co-founded by Jonathan Milner, PhD and Yichen Shi, PhD whose combined expertise and entrepreneurial spirit was the driving force behind the creation of Axol - where innovation, quality and customer service are key. Axol produces highly validated, human cells and critical reagents such as media and growth supplements. The Axol team is passionate about great science, delivering superb customer service and support and innovating future products to help customers advance their research faster. To find out more, visit www.axolbio.com


Share this Post:
read previous

Axol Bioscience Appoints Steve Finkbeiner as Scientific Advisory Board Member

read next

SLAS 2016 Posters